The Effect of Borderline Pulmonary Hypertension on Survival in Chronic Lung Disease

Author:

Piccari LucillaORCID,Wort Stephen John,Meloni Federica,Rizzo MonicaORCID,Price Laura C.ORCID,Martino Lavinia,Salvaterra Elena,Scelsi LauraORCID,López Meseguer ManuelORCID,Blanco IsabelORCID,Callari Adriana,Pérez González Virginia,Tuzzolino Fabio,McCabe Colm,Rodríguez Chiaradía Diego Agustín,Vitulo Patrizio,

Abstract

<b><i>Background:</i></b> The impact of the new “borderline” hemodynamic class for pulmonary hypertension (PH) (mean pulmonary artery pressure [mPAP], 21–24 mm Hg and pulmonary vascular resistance, [PVR], ≥3 wood units, [WU]) in chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD) is unclear. <b><i>Objectives:</i></b> The aim of this study was to assess the effect of borderline PH (BLPH) on survival in COPD and ILD patients. <b><i>Method:</i></b> Survival was analyzed from retrospective data from 317 patients in 12 centers (Italy, Spain, UK) comparing four hemodynamic groups: the absence of PH (NoPH; mPAP &#x3c;21 mm Hg or 21–24 mm Hg and PVR &#x3c;3 WU), BLPH (mPAP 21–24 mm Hg and PVR ≥3 WU), mild-moderate PH (MPH; mPAP 25–35 mm Hg and cardiac index [CI] ≥2 L/min/m<sup>2</sup>), and severe PH (SPH; mPAP ≥35 mm Hg or mPAP ≥25 mm Hg and CI &#x3c;2 L/min/m<sup>2</sup>). <b><i>Results:</i></b> BLPH affected 14% of patients; hemodynamic severity did not predict survival when COPD and ILD patients were analyzed together. However, survival in the ILD cohort for any PH level was worse than in NoPH (3-year survival: NoPH 58%, BLPH 32%, MPH 28%, SPH 33%, <i>p</i> = 0.002). In the COPD cohort, only SPH had reduced survival compared to the other groups (3-year survival: NoPH 82%, BLPH 86%, MPH 87%, SPH 57%, <i>p</i> = 0.005). The mortality risk correlated significantly with mPAP in ILD (hazard ratio [HR]: 2.776, 95% CI: 2.057–3.748, <i>p</i> &#x3c; 0.001) and notably less in COPD patients (HR: 1.015, 95% CI: 1.003–1.027, <i>p</i> = 0.0146). <b><i>Conclusions:</i></b> In ILD, any level of PH portends worse survival, while in COPD, only SPH presents a worse outcome.

Publisher

S. Karger AG

Subject

Pulmonary and Respiratory Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3